CN1073626C - Productive technology for A type botulism crystalline toxin and frozen-dried protective liquid needed for producing said toxin - Google Patents

Productive technology for A type botulism crystalline toxin and frozen-dried protective liquid needed for producing said toxin Download PDF

Info

Publication number
CN1073626C
CN1073626C CN97118838A CN97118838A CN1073626C CN 1073626 C CN1073626 C CN 1073626C CN 97118838 A CN97118838 A CN 97118838A CN 97118838 A CN97118838 A CN 97118838A CN 1073626 C CN1073626 C CN 1073626C
Authority
CN
China
Prior art keywords
toxin
liquid
frozen
freeze
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN97118838A
Other languages
Chinese (zh)
Other versions
CN1215084A (en
Inventor
王荫椿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lanzhou Institute of Biological Products Co., Ltd.
Original Assignee
LANZHOU INST OF BIOLOGICAL PRODUCTS MINISTRY OF PUBLIC HEALTH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LANZHOU INST OF BIOLOGICAL PRODUCTS MINISTRY OF PUBLIC HEALTH filed Critical LANZHOU INST OF BIOLOGICAL PRODUCTS MINISTRY OF PUBLIC HEALTH
Priority to CN97118838A priority Critical patent/CN1073626C/en
Publication of CN1215084A publication Critical patent/CN1215084A/en
Application granted granted Critical
Publication of CN1073626C publication Critical patent/CN1073626C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a microbial toxin, and an obtained product belongs to a new biological product. The microbial toxin is used for curing the myodystonia diseases, such as blepharospasm, facial spasm, strabismus, spasmodic torticollis, etc., in the fields of departments of neurology, ophthalmology, etc. The technology of the present invention comprises the steps of preparation of a toxin producing culture medium, cultivation for producing toxins, sterilization, filtration, refining and purification of the toxins, and dilution and freeze drying of the toxins. The product prepared by the present invention has the advantages of high toxin yield, good quality, long validity period, low cost, etc.

Description

The production technique of A type meat poison crystalline toxin and produce the required frozen-dried protective liquid of this toxin
The present invention relates to microbial toxin, resulting product belongs to new biological products, is used for the myodystonia disease in fields such as neurology department, ophthalmology, as: the treatment of blepharospasm, mimic convulsion, stravismus and spasmodic torticollis etc.
Botulinum toxin type A is the extremely strong neurotoxin of a kind of virulence that produces in the A type Clostridium botulinum growth and breeding process, and it can act on the motor nerve ending myoneural junction, suppresses presynaptic membrane and discharges vagusstoff, thereby cause the flaccidity paralysis.The pharmacological action of this uniqueness, listed in clinical the beginning of the eighties by American scholar, diseases such as stravismus, blepharospasm, mimic convulsion and spasmodic torticollis are carried out therapeutic trial, and obtain satisfied curative effect.In December, 1989, U.S. FOA official approval botulinum toxin type A (trade(brand)name Oculinum) is gone into operation as new drug and is gone on the market.In February, 1989, " injection botulinus toxin " that I developed goes through to carry out clinical trial, and be new drug by Ministry of Health's approval in October, 1993, formally transfers accurate font size in February, 1997 to | and (97) defend the accurate word of medicine (orchid) S-01 number | go into operation.
The U.S. adopts at present; Clostridium botulinum is cultivated Acid precipitation entirely, and--the toxin phosphate buffered saline buffer extracts the concentrated spontaneous nucleation supervisor that reaches of--cold ethanol precipitation--ammonium sulfate and prepares A type meat poison crystalline toxin.All higher with botulinum toxin type A purity, quality that this kind method is produced, but have certain problem and limitation in technology, consumption, safety, aspect stable, be listed below:
1, toxin producing medium composition N-2Amine (Sheffied), Yeast extract (Oifco) etc. all is the dry powder finished product of single-minded manufacturer production, costs an arm and a leg.
2, cultivate the purification toxin entirely with thalline, easily cause brood cell's (belonging to two bacterioids) of laboratory environment and facility to pollute, have serious risk and harm.
3, one of step of purification botulinum toxin type A, the cold ethanol precipitation needs specific low temperature factory building and facility.The pure toxin yield rate of this technology is lower in addition, only is 17%.
4, product is made the dry toxin of protection liquid cooling freeze-drying with human serum albumin, the danger that exists the blood source to pollute, and toxin power in the freeze-drying process (being unit) is lost up to 50-90%; The poor stability of freeze-drying finished product, validity period is short.Merge it;
3, enzyme is handled and concentrated: extracting solution press 100ug/ml and is added rnase, 35 ℃ of incubations 3 hours, and it is saturated to add ammonium sulfate to 60%, and 2-8 ℃ is spent the night, centrifugal, and precipitation is dialysed after dissolving with an amount of PH5.5,0.05M citrate buffer solution;
4, chromatography: dialyzate is collected, is merged 00 through the OEAE-ASO ion exchange chromatography 260~00 280Post liquid excessively for 0.5-0.6;
5, crystallization: it is saturated that amalgamation liquid adds ammonium sulfate to 60%, and 2-8 ℃ is spent the night, centrifugal, precipitation is dialysed in containing the above-mentioned damping fluid of 0.9M ammonium sulfate with an amount of PH6.8, the dissolving of 0.05M phosphate buffered saline buffer again, forms crystallization naturally, also can repeat said process, to form crystallization for the second time;
The dilution of VI, toxin, freeze-drying
1, dilution
A, with phosphate buffered saline buffer dissolving and percrystallization toxin, measure virulence after the Sterile Filtration;
B, the toxin soiutions of known virulence is diluted to proper concn (10 with phosphate buffered saline buffer 5-10 6L0 50/ ml);
C, an amount of dilution toxin is joined in the quantitative frozen-dried protective liquid, make in every milliliter of frozen-dried protective liquid content of toxins at the scope (50-100L0 that tires and require 50/ ml);
2, packing, freeze-drying
Every peace bottle is 1 milliliter of the above-mentioned toxin dilution that contains frozen-dried protective liquid of packing quantitatively, with the freeze-drying curve of protein articles it is carried out freeze-drying, and the freeze-drying finished product should be aseptic, water content is no more than 3%.
2, a kind of required frozen-dried protective liquid of A type meat poison crystalline toxin of producing is characterized in that:
1, composition
Gelatin 1%
Dextran 5%
Sucrose 5%
Distilled water adds to 100ml
2, compound method
A, weigh gelatin by amount of preparation, back high pressure (121 ℃) sterilization 30 minutes is dissolved in heating;
B, add dextran and sucrose in proportion, treat off-bottom after, filter bulb filters, BP (113 ℃) sterilization 30 minutes is stand-by.
A, Acid precipitation; Parent toxin liquid adds Sodium hexametaphosphate 99, makes ultimate density reach 0.2%, transfers about PH to 3.5 with 3 equivalent hydrochloric acid, and 2-8 ℃ is spent the night;
B, toxin extract; Abandon supernatant, precipitation adds an amount of PH6.0,0.2M phosphate buffered saline buffer with distillation washing 1 time, divides 2 dissolvings, extraction, puts room temperature 1 hour at every turn, gets supernatant liquor respectively after centrifugal and merges it;
C, enzyme are handled and are concentrated; Extracting solution is pressed 100ug/ml and is added rnase, 35 ℃ of incubations 3 hours, it is saturated to add ammonium sulfate to 60%, 2-8 ℃ is spent the night, centrifugal, precipitation with an amount of PH5.5, the dissolving of 0.05M citrate buffer solution after, dialyse;
D, chromatography: dialyzate is collected, is merged 00 through the OEAE-ASO ion exchange chromatography 260/ 00 280Post liquid excessively for 0.5-0.6;
E, crystallization: it is saturated that amalgamation liquid adds ammonium sulfate to 60%, and 2-8 ℃ is spent the night.Centrifugal, precipitation is dialysed in containing the above-mentioned damping fluid of 0.9M ammonium sulfate with an amount of PH6.8, the dissolving of 0.05M phosphate buffered saline buffer again, forms crystallization naturally.Also can repeat said process, to form crystallization for the second time;
(6), the dilution of toxin, freeze-drying
(1), dilution
A, with phosphate buffered saline buffer dissolving and percrystallization toxin, measure virulence after the Sterile Filtration;
6, with phosphate buffered saline buffer the toxin soiutions of known virulence is diluted to proper concn (10 5-10 6L0 50/ ml);
C, an amount of dilution toxin is joined in the quantitative frozen-dried protective liquid, make in every milliliter of frozen-dried protective liquid content of toxins at the scope (50-100L0 that tires and require 50/ ml);
(2), packing, freeze-drying
Every peace bottle is 1 milliliter of the above-mentioned toxin dilution that contains frozen-dried protective liquid of packing quantitatively, with the freeze-drying curve of protein articles it is carried out freeze-drying.The freeze-drying finished product should be aseptic, moisture content is no more than 3%.
Required its composition of frozen-dried protective liquid in the above-mentioned A type meat poison crystalline toxin production process;
Gelatin 1%
Dextran 5%
Sucrose 5%
Distilled water adds to 100ml
Compound method:
(1), weigh gelatin, back high pressure (121 ℃) sterilization 30 minutes is dissolved in heating by amount of preparation;
(2), in proportion add dextran and sucrose, treat off-bottom after, filter bulb filters, BP (113 ℃) sterilization 30 minutes is stand-by.
Beneficial effect of the present invention:
1, the toxin yield rate brings up to 33% by 17% in the background technology, thereby has reduced cost effectively, has kept the low price of finished product, is fit to the national conditions and the level of consumption.
2, quality contrasts the single pin of the project U.S. single needle crystal of resulting product form of the present invention, bar-shaped crystallization purity 3.0 * 10 well 7L0 50(± 20%)/mgpt 2.5-3.0 * 10 7L0 50/ mgpt ※ 00 260/ 00 280<0.6≤0.55
The low more toxin of this number of ※ is pure more
3, the application of frozen-dried protective liquid makes in the freeze-drying process virulence loss be reduced to 0-20%, and has prolonged the validity period (goods of the present invention are 3 years, and the U.S. is 2 years) of goods;
4, factory building, facility, the equipment of the present invention's requirement are simpler, and toxin is purified and can be carried out at normal temperatures, and simple and easy to do, good reproducibility;
5, purify with removing verticillium toxin, cultivate entirely with thalline than background technology and purify saferly, avoided the danger of Clostridium botulinum brood cell contaminate environment;
6, produce poison and cultivate available domestic raw material, self-control, both can reduce import, save foreign exchange, can suit measures to local conditions again, guarantee supply.

Claims (2)

1, a kind of production technique of A type meat poison crystalline toxin is characterized in that:
I, toxin producing medium composition
Casein trysinization liquid 50%
Yeast dialyzate 20%
Distilled water 30%
Wherein: casein trysinization liquid composition
Casein C, P 100g
Distilled water 1000ml
Pancreas enzyme powder (unit of activity is more than 1: 100) 8.8 unit of activity/lg casein
II, toxin producing medium form
(1), casein trysinization liquid is mixed with distilled water, heat 50-60 ℃,, boil the back and add the yeast dialyzate, boiled again 10 minutes, transfer PH to 7.4 again with 20% sodium hydroxide with 20% sodium hydroxide solution levelling PH7.0;
(2), boil, filter paper filtering, the upright bottle of packing, standby in 113 ℃ of sterilizations in 30 minutes;
(3), in addition join 50% glucose solution in 113 ℃ of sterilizations in 30 minutes, add during inoculation, ultimate density reaches 1%;
III, product poison are cultivated
To be inoculated in the toxin producing medium of 18.000-36.000ml through adapting to A type Clostridium botulinum (Hall strain) bacterial classification after cultivating, cultivated 5 days for 35 ℃;
IV, Sterile Filtration
After microscopy is pure culture, with no asbestos degerming plate or degerming membrane filtration, get parent toxin liquid, measure virulence with small white mouse, virulence should be 10 6L0 50About/ml;
The refining purification of V, toxin
(1), Acid precipitation; Parent toxin liquid adds Sodium hexametaphosphate 99, makes ultimate density reach 0.2%, transfers about PH to 3.5 with 3 equivalent hydrochloric acid, and 2-8 ℃ is spent the night;
(2), toxin extracts; Abandon supernatant, precipitation adds an amount of PH6.0,0.2M phosphate buffered saline buffer with distillation washing 1 time, dissolves at twice, extracts, and puts room temperature 1 hour at every turn, gets supernatant liquor respectively after centrifugal and merges it;
(3), enzyme is handled and concentrate: extracting solution press 100ug/ml and is added rnase, 35 ℃ of incubations 3 hours, it is saturated to add ammonium sulfate to 60%, 2-8 ℃ is spent the night, centrifugal, precipitation is dialysed after dissolving with an amount of PH 5.5,0.05M citrate buffer solution;
(4), chromatography: dialyzate is collected, is merged 00 through the 0AEE-ASO ion exchange chromatography 260~002 280Post liquid excessively for 0.5-0.6;
(5), crystallization: it is saturated that amalgamation liquid adds ammonium sulfate to 60%, and 2-8 ℃ is spent the night, centrifugal, precipitation is dialysed in containing the above-mentioned damping fluid of 0.9M ammonium sulfate with an amount of PH6.8, the dissolving of 0.05M phosphate buffered saline buffer again, forms crystallization naturally, also can repeat said process, to form crystallization for the second time;
The dilution of VI, toxin, freeze-drying
(1), dilution
A, with phosphate buffered saline buffer dissolving and percrystallization toxin, measure virulence after the Sterile Filtration;
B, the toxin soiutions of known virulence is diluted to proper concn (10 with phosphate buffered saline buffer 5-10 6L0 50/ ml);
C, an amount of dilution toxin is joined in the quantitative frozen-dried protective liquid, make in every milliliter of frozen-dried protective liquid content of toxins at the scope (50-100L0 that tires and require 50/ ml);
(2), packing, freeze-drying
Every peace bottle is 1 milliliter of the above-mentioned toxin dilution that contains frozen-dried protective liquid of packing quantitatively, with the freeze-drying curve of protein articles it is carried out freeze-drying, and the freeze-drying finished product should be aseptic, water content is no more than 3%.
2, a kind of required frozen-dried protective liquid of A type meat poison crystalline toxin of producing is characterized in that:
(1), composition
Gelatin 1%
Dextran 5%
Sucrose 5%
Distilled water adds to 100ml
(2), compound method
A, weigh gelatin by amount of preparation, back high pressure (121 ℃) sterilization 30 minutes is dissolved in heating;
B, add dextran and sucrose in proportion, treat off-bottom after, filter bulb filters, BP (113 ℃) sterilization 30 minutes is stand-by.
CN97118838A 1997-10-18 1997-10-18 Productive technology for A type botulism crystalline toxin and frozen-dried protective liquid needed for producing said toxin Expired - Lifetime CN1073626C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN97118838A CN1073626C (en) 1997-10-18 1997-10-18 Productive technology for A type botulism crystalline toxin and frozen-dried protective liquid needed for producing said toxin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN97118838A CN1073626C (en) 1997-10-18 1997-10-18 Productive technology for A type botulism crystalline toxin and frozen-dried protective liquid needed for producing said toxin

Publications (2)

Publication Number Publication Date
CN1215084A CN1215084A (en) 1999-04-28
CN1073626C true CN1073626C (en) 2001-10-24

Family

ID=5175001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97118838A Expired - Lifetime CN1073626C (en) 1997-10-18 1997-10-18 Productive technology for A type botulism crystalline toxin and frozen-dried protective liquid needed for producing said toxin

Country Status (1)

Country Link
CN (1) CN1073626C (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
BR112019004929A2 (en) 2016-09-13 2019-06-04 Allergan Inc non-protein clostridial toxin compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EYE 2 1988.1.1;MICRO REN VOL.56 NO.1 1992.1.1 *

Also Published As

Publication number Publication date
CN1215084A (en) 1999-04-28

Similar Documents

Publication Publication Date Title
US11525130B2 (en) Process and system for obtaining botulinum neurotoxin
CN1856569B (en) Animal product free process for obtaining a botulinum toxin and culture medium
JPS60251898A (en) Preparation of hyaluronic acid by fermentation method
CA2556796A1 (en) Animal product free system and process for purifying a botulinum toxin
IE843003L (en) Ultrapure hyaluronic acid
CN1073626C (en) Productive technology for A type botulism crystalline toxin and frozen-dried protective liquid needed for producing said toxin
CN108342434A (en) A kind of clostridium septicum toxin for animals and preparation method thereof and special culture media
CN1202234C (en) Honey wine and its prepn
CN110438027A (en) Produce the Bacillus amyloliquefaciens strain GUTU06 and its screening technique of a variety of enzymes
CN100577149C (en) Novel lyophilization protecting agent prescription of A type botulinum toxin freeze-dried powder injection preparation for treatment
CN101204577A (en) Process for preparing crystal composite of BTX-A
CN109456898A (en) A kind of the fermentation preparation and its application of chaetomium globosum dextranase
CN102154416B (en) Immobilized microbial cell method for converting ganglioside
CN101709083B (en) Fibrinolytic protein from scorpion tails, preparation method and application thereof
Gill CULTURE AND METABOLISM OF MYCOPLASMA GLLISEPTICUM
KR880001949B1 (en) Process for preparing hyaluronic acid
JPS62257393A (en) Production of hyaluronic acid
JPS62257382A (en) Novel streptococcus zooepidemicus
JPH01174383A (en) Production of n-acetylchitooligosaccharide by enzyme
JPS60163895A (en) Production of glycyrrhezic acid
DE2000494A1 (en) Elastase enzyme prodn by bacterial fermen - tation
CN1101941A (en) Method for suspending, adsorbing and multiplicating virus of hepatitis A
JPH0634750B2 (en) Method for producing D-isoserine
CN1369551A (en) Hay bacillus for preparing elastase

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.

Free format text: FORMER OWNER: LANZHOU INST. OF BIOLOGICAL PRODUCTS, MINISTRY OF PUBLIC HEALTH

Effective date: 20120816

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120816

Address after: 730046 Gansu Province Chengguan District of Lanzhou City saltworks Road No. 888

Patentee after: Lanzhou Institute of Biological Products Co., Ltd.

Address before: 730046 Gansu province Lanzhou City saltern Road No. 118

Patentee before: Lanzhou Inst. of Biological Products, Ministry of Public Health

CX01 Expiry of patent term

Granted publication date: 20011024

CX01 Expiry of patent term